

THIRD. Ratification of the fifth agreement adopted by the General Shareholders' Meeting held on October 31, 2024, regarding the delegation to the Board of Directors of the authority to increase the share capital, with the power to exclude the pre-emptive subscription right under Article 297.1.b) of the Capital Companies Act.

It is agreed to fully ratify the content of the fifth agreement adopted by the General Shareholders' Meeting of the Company in its session held on October 31, 2024, in accordance with its literal wording:

***Fifth.** Delegation to the Board of Directors of the Company to increase the share capital, with the power to exclude the pre-emptive subscription right under Article 297.1.b) of the Capital Companies Act, and derived from the investment agreement signed with LDA CAPITAL LIMITED.*

As a result of the investment agreement signed by the Company with LDA CAPITAL LIMITED, it is unanimously agreed by the Shareholders to delegate to the Board of Directors, under the provisions of Article 297.1.b), 504, and 506 of the Capital Companies Act, the authority to increase the share capital, without prior consultation with the General Shareholders' Meeting, within the period set for this purpose and up to the maximum limit and amount provided for in the Capital Companies Act, amending the article of the Company's Bylaws related to the share capital, in accordance with the following conditions:

A. Capital Increases and Delegation Period

The Board of Directors is authorized, as broadly as necessary under the law, to increase the share capital, without prior consultation with the General Shareholders' Meeting, in one or several occasions and at any time, within a period of five years from the date of this Ordinary General Shareholders' Meeting, up to an amount corresponding to 50% of the share capital at the time of authorization (i.e., 32,437.62 euros in nominal value), through the issuance of new ordinary shares or any other type of shares in accordance with applicable legal requirements—with or without an issuance premium—with the consideration for the new shares to be issued consisting of cash contributions. For clarification purposes, the indicated percentage of share capital will be cumulative with respect to any share capital increases that may be carried out, if applicable, under the previous fourth item on the agenda.

B. Scope of the Delegation

The Board of Directors may set all the terms and conditions of the capital increases and the characteristics of the shares, as well as determine the investors and markets to which the capital increases are directed and the placement procedure to be followed, freely offer the new shares not subscribed during the preferential subscription period, and establish, in case of incomplete subscription, that the capital increase be void or that the capital be increased only by the amount of the subscriptions made, and amend the article of the Company's Bylaws related to the share capital.

The Board of Directors may designate the person or persons, whether or not they are directors, who are to execute any of the agreements adopted under this authorization, and particularly the closing of the capital increase.

C. Rights of the New Shares, Type of Issuance, and Consideration for the Increase

The new shares issued as a result of the capital increase or increases agreed under this delegation will be ordinary shares with the same rights as the existing ones (except for dividends already declared and pending payment at the time of their issuance), which will be issued at their nominal value or with the issuance premium, if any, as determined. The consideration for the new shares to be issued will necessarily consist of cash contributions.

D. Exclusion of the Pre-emptive Subscription Right

In accordance with the provisions of Article 506 of the Capital Companies Act, the Board of Directors is expressly granted the authority to exclude, in whole or in part, the pre-emptive subscription right with respect to all or any of the issuances it decides to carry out under this authorization, provided that the capital increases carried out under this delegation do not exceed an amount equivalent to 20% of the Company's share capital at the date of effectiveness of this agreement (i.e., 12,975.05 euros in nominal value).

In accordance with applicable legislation, the Board of Directors may exercise the authority granted under the previous paragraph when the interest of the Company so requires, and at the time of agreeing to the increase, it will issue a detailed report outlining the specific reasons of social interest justifying such measure, accompanied, if legally necessary or if the Board of Directors decides to obtain it voluntarily, by the independent expert report provided for in Article 308 of the Capital Companies Act. These reports will be made available to the shareholders and communicated to the first General Shareholders' Meeting held after the capital increase agreement, in accordance with the provisions of the Article 506 and 504 of the same legal text.

E. Admission to Trading of the Issued Shares

The Board of Directors is authorized to request the admission to trading, and their exclusion, in the multilateral trading systems and/or organized secondary markets, Spanish or foreign, of the shares that may be issued or, in case of modification of the nominal value of the already issued shares, their exclusion and new admission, complying with the applicable rules regarding trading, permanence, and exclusion from trading.

F. Substitution Authority

The Board of Directors is authorized to delegate, in turn, to any of the members of the Board of Directors or to any other person, whether a member of that body, the delegated authorities referred to in this agreement.

It is noted that the corresponding report of the directors justifying the proposal for delegation to increase the share capital with the exclusion of pre-emptive subscription rights has been made available to the shareholders, which is incorporated as Annex VIII.

For the purposes of the provisions of Article 197.bis of the Capital Companies Act, it is expressly stated that all the agreements contained in this item have been subject to separate voting and approval."